HRP20110253T1 - Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze - Google Patents

Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze Download PDF

Info

Publication number
HRP20110253T1
HRP20110253T1 HR20110253T HRP20110253T HRP20110253T1 HR P20110253 T1 HRP20110253 T1 HR P20110253T1 HR 20110253 T HR20110253 T HR 20110253T HR P20110253 T HRP20110253 T HR P20110253T HR P20110253 T1 HRP20110253 T1 HR P20110253T1
Authority
HR
Croatia
Prior art keywords
inhibitors
antagonists
agonists
compound according
compound
Prior art date
Application number
HR20110253T
Other languages
English (en)
Croatian (hr)
Inventor
Manuel Vieira Ara�jo Soares Da Silva Patr�cio
Alexander Learmonth David
Beliaev Alexander
Original Assignee
Bial-Portela & Ca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110253(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial-Portela & Ca filed Critical Bial-Portela & Ca
Publication of HRP20110253T1 publication Critical patent/HRP20110253T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20110253T 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze HRP20110253T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
HRP20110253T1 true HRP20110253T1 (hr) 2011-05-31

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110253T HRP20110253T1 (hr) 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze

Country Status (29)

Country Link
US (5) US8481582B2 (enExample)
EP (1) EP2155731B1 (enExample)
JP (1) JP5559677B2 (enExample)
KR (1) KR101598482B1 (enExample)
CN (1) CN101687858B (enExample)
AR (2) AR066457A1 (enExample)
AT (1) ATE499367T1 (enExample)
AU (1) AU2008246443B2 (enExample)
BR (1) BRPI0811275B8 (enExample)
CA (1) CA2686387C (enExample)
CL (1) CL2008001321A1 (enExample)
CY (1) CY1111517T1 (enExample)
DE (1) DE602008005141D1 (enExample)
DK (1) DK2155731T3 (enExample)
ES (1) ES2360841T3 (enExample)
GB (1) GB0708818D0 (enExample)
HR (1) HRP20110253T1 (enExample)
IL (1) IL201921A (enExample)
MX (1) MX2009012041A (enExample)
NO (1) NO20093275L (enExample)
NZ (1) NZ580962A (enExample)
PL (1) PL2155731T3 (enExample)
RS (1) RS51692B (enExample)
RU (1) RU2501796C2 (enExample)
SI (1) SI2155731T1 (enExample)
TW (1) TWI458722B (enExample)
UA (1) UA104844C2 (enExample)
WO (1) WO2008136695A1 (enExample)
ZA (1) ZA200908612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
BR112013015864B1 (pt) 2010-12-22 2021-11-09 Bial - Portela & C.A., S.A. Processo para purificar um composto de forma cristalina a de (r)-5-(2-benzilamino)etil)-1- (6,8-difluorocroman-3-il)-1h-imidazol-2(3h)-tiona
US9346751B2 (en) 2011-06-29 2016-05-24 Bial-Portela & Ca, S.A. Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives
EP2919780B1 (en) 2012-11-14 2018-08-01 BIAL - Portela & CA., S.A. 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
WO2019112457A1 (en) * 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
CN113166053A (zh) * 2018-11-12 2021-07-23 伊缪诺金公司 制备细胞毒性苯二氮䓬衍生物的方法
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
AU2022213938A1 (en) * 2021-01-26 2023-09-07 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pathway modulator, pharmaceutical composition having same, use thereof, and therapeutic method using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
EP0757677B1 (en) 1994-04-26 2003-06-18 Syntex (U.S.A.) LLC Benzocyclohexylimidazolethione derivatives
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
RU2501796C2 (ru) 2013-12-20
CL2008001321A1 (es) 2008-12-26
ATE499367T1 (de) 2011-03-15
US8481582B2 (en) 2013-07-09
AU2008246443A8 (en) 2010-01-07
AU2008246443A1 (en) 2008-11-13
KR101598482B1 (ko) 2016-02-29
NZ580962A (en) 2012-05-25
EP2155731A1 (en) 2010-02-24
US20170369478A1 (en) 2017-12-28
JP2010526136A (ja) 2010-07-29
CY1111517T1 (el) 2015-08-05
PL2155731T3 (pl) 2011-07-29
BRPI0811275B8 (pt) 2021-05-25
DK2155731T3 (da) 2011-05-02
CN101687858A (zh) 2010-03-31
US20130345275A1 (en) 2013-12-26
ES2360841T3 (es) 2011-06-09
RU2009145270A (ru) 2011-06-20
BRPI0811275B1 (pt) 2020-01-07
CA2686387A1 (en) 2008-11-13
UA104844C2 (uk) 2014-03-25
TWI458722B (zh) 2014-11-01
DE602008005141D1 (de) 2011-04-07
KR20100017546A (ko) 2010-02-16
AR112789A2 (es) 2019-12-11
IL201921A0 (en) 2010-06-16
ZA200908612B (en) 2010-11-24
CN101687858B (zh) 2012-12-26
BRPI0811275A2 (pt) 2014-12-23
RS51692B (sr) 2011-10-31
TW200918525A (en) 2009-05-01
US9630951B2 (en) 2017-04-25
AU2008246443B2 (en) 2013-07-11
JP5559677B2 (ja) 2014-07-23
US20210261533A1 (en) 2021-08-26
EP2155731B1 (en) 2011-02-23
HK1142898A1 (en) 2010-12-17
CA2686387C (en) 2015-06-30
IL201921A (en) 2013-11-28
NO20093275L (no) 2010-02-04
AR066457A1 (es) 2009-08-19
US20100137390A1 (en) 2010-06-03
GB0708818D0 (en) 2007-06-13
US20190322648A1 (en) 2019-10-24
SI2155731T1 (sl) 2011-05-31
WO2008136695A1 (en) 2008-11-13
MX2009012041A (es) 2010-02-18

Similar Documents

Publication Publication Date Title
HRP20110253T1 (hr) Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze
JP2010526136A5 (enExample)
JP7252972B2 (ja) ３－ヒドロキシ－Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ピロリジン－１－カルボキサミド誘導体
KR101500766B1 (ko) 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법
JP6622299B2 (ja) テトラヒドロイソキノリン誘導体
Yin et al. Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019
US11008302B2 (en) Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
RU2009132881A (ru) Производные пуринила и их применение в качестве модуляторов калиевых каналов
PE20050462A1 (es) COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5)
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
NO20083690L (no) Hydantoin baserte kinase-inhibitorer
EP3464281A1 (en) Mutant idh1 inhibitors
Song et al. Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
AU2018225312A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
Clark et al. Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists
Vangveravong et al. Synthesis of N-substituted 9-azabicyclo [3.3. 1] nonan-3α-yl carbamate analogs as σ2 receptor ligands
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
US9867826B2 (en) Heterocycles as modulators of kinase activity
Herp et al. First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement
EP4310077A1 (en) Bicyclic phenol compounds and use thereof
Aizpurua et al. Discovery of a novel family of FKBP12 “reshapers” and their use as calcium modulators in skeletal muscle under nitro-oxidative stress
TW201718475A (zh) 尿素衍生物及其用途
MX2010001229A (es) Procedimiento para la resolucion de zopiclona y compuestos intermedios.
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés